An advisory panel to the FDA voted for the approval of Schering-Plough"s asenapine in addition voted 12-0 in favor of its use in treating manic or mixed episodes of bipolar disorder. The new antipsychotic drug will be marketed as Saphris. The panel found that its benefits outweighed side-effects in adults with schizophrenia although these medications have caused concern about weight gain. According to Schering-Plough studies done by the company indicated that fewer patients taking asenapine experienced higher levels cholesterol or increased tendency to gain weight. Some of the panel did suggest that a 10 milligram dose might be too much in some patients with bipolar disorder and proper dosage is important.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지